Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series.
Vesole DH, Richter J, Biran N, McBride L, Anand P, Huang M, Kumeli AZ, Klippel Z, Iskander K, Siegel DS. Vesole DH, et al. Among authors: huang m. Leuk Lymphoma. 2018 Jan;59(1):259-261. doi: 10.1080/10428194.2017.1321749. Epub 2017 Jun 5. Leuk Lymphoma. 2018. PMID: 28583038 No abstract available.
Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.
Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH. Dimopoulos MA, et al. Among authors: huang m, huang sy. Int J Hematol. 2019 Oct;110(4):466-473. doi: 10.1007/s12185-019-02704-z. Epub 2019 Aug 6. Int J Hematol. 2019. PMID: 31388932 Clinical Trial.
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK. Moreau P, et al. Among authors: huang m. Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1. Lancet Oncol. 2018. PMID: 29866475 Clinical Trial.
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
Mesa R, Harrison C, Oh ST, Gerds AT, Gupta V, Catalano J, Cervantes F, Devos T, Hus M, Kiladjian JJ, Lech-Maranda E, McLornan D, Vannucchi AM, Platzbecker U, Huang M, Strouse B, Klencke B, Verstovsek S. Mesa R, et al. Among authors: huang m. Leukemia. 2022 Sep;36(9):2261-2268. doi: 10.1038/s41375-022-01637-7. Epub 2022 Jul 22. Leukemia. 2022. PMID: 35869266 Free PMC article. Clinical Trial.
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Falchook GS, et al. Among authors: huang m. Oncotarget. 2014 Nov 15;5(21):10280-92. doi: 10.18632/oncotarget.2163. Oncotarget. 2014. PMID: 25373733 Free PMC article. Clinical Trial.
17,429 results
You have reached the last available page of results. Please see the User Guide for more information.